| Autor: |
Carolynn M, Dude, Naima T, Joseph, Alexandra D, Forrest, Hans P, Verkerke, Narayanaiah, Cheedarla, Sakthivel, Govindaraj, Les'Shon S, Irby, Kirk A, Easley, Alicia K, Smith, Sean R, Stowell, Andrew, Neish, Rama Rao, Amara, Denise J, Jamieson, Anne L, Dunlop, Martina L, Badell, Vijayakumar, Velu |
| Rok vydání: |
2022 |
| Zdroj: |
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. |
| ISSN: |
1879-3479 |
| Popis: |
Understanding of the immune response following COVID-19 vaccination in pregnancy is limited by small cohort size and little data on neutralizing antibody.This was a prospective cohort study comprising patients with PCR confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, Georgia, USA. Maternal and cord blood at delivery was assayed for anti-Receptor Binding Domain (RBD) -IgG, -IgA and -IgM and neutralizing antibody. The detection of antibodies, titers, and maternal-to-fetal transfer ratios were compared.Nearly all patients had detectable RBD-IgG in maternal and cord samples. The vaccinated vs. infected cohort had a significantly greater proportion of cord samples with detectable neutralizing antibody (94% vs 28%, p 0.0001) and significantly higher transfer ratios for RBD-IgG and neutralizing antibodies with a transfer efficiency of 105% (vs 80%, p 0.0001) and 110% (vs 90%, p 0.0001), respectively. There was a significant linear decline in maternal and cord blood RBD-IgG and neutralizing antibody titers as time from vaccination to delivery increased.Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to - if not greater than- those naturally infected by SARS-CoV-2 during pregnancy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text